Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 8/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889250 | 0.94 | DGKA (0.48) | DGKALTA4HACHEDNM1ALDH1A1 | |
| SCHEMBL10351184 | 0.92 | DGKA (0.52) | DGKALTA4HACHEDNM1CA12 | |
| SCHEMBL23326932 | 0.89 | NAAA (0.58) | DGKAACHEDNM1NAAAHTR2C | |
| SCHEMBL889329 | 0.89 | NAAA (0.58) | DGKAACHEDNM1NAAAHTR2C | |
| SCHEMBL13659026 | 0.88 | DGKA (0.55) | DGKALTA4HACHEDNM1ALDH1A1 | |
| SCHEMBL889155 | 0.88 | ALDH1A1 (0.45) | DGKALTA4HDNM1ALDH1A1GLA | |
| SCHEMBL16079775 | 0.87 | DGKA (0.55) | DGKALTA4HACHEDNM1CA12 | |
| SCHEMBL11231987 | 0.87 | DGKA (0.46) | DGKALTA4HDNM1CA12CA14 | |
| SCHEMBL5011369 | 0.86 | LTA4H (0.50) | DGKALTA4HACHECA12CA14 | |
| SCHEMBL11386401 | 0.85 | DGKA (0.44) | DGKALTA4HDNM1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079366-A1 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | THE BROAD INSTITUTE, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079366-A1 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | RBM12, CPSF6, CPSF1 | DGKA 3175/4885LTA4H 4653/4885ACHE 4799/4885 |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | DGKA 1291/4885LTA4H 253/4885ACHE 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.